New drug targets Hard-to-Treat cancers in early trial
NCT ID NCT07083323
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new drug called HY05350 in people with advanced solid tumors that have a protein called MSLN on their surface. The trial has two parts: first, finding a safe dose, and second, seeing if the drug shrinks tumors. About 262 participants who have exhausted standard treatments will receive the drug intravenously on a weekly or biweekly schedule.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HY05350 (an investigational drug given intravenously)
What this could lead to
If successful, this could lead to a new treatment option for people with advanced solid tumors that have a specific marker (MSLN) and have not responded to standard therapies.
What could go wrong
This is an early-phase trial (Phase 1/2) with a small number of participants, so the drug may not prove effective or may have significant side effects. It is also only for patients with MSLN-positive tumors, limiting who can benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Peking University Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, 100142, China
Contact